Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.73 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258907 | 0.88 | HRH3 (0.55) | LOXL2TAAR1HRH3ABAT | |
| SCHEMBL1459020 | 0.85 | HRH3 (0.52) | LOXL2TAAR1HRH3ABAT | |
| SCHEMBL21063 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL3830237 | 0.83 | LOXL2 (0.94) | LOXL2MAOBTAAR1HRH3IDO1 | |
| Iodide SCHEMBL20838270 | 0.83 | LOXL2 (0.94) | LOXL2MAOBTAAR1HRH3IDO1 | |
| Hydrochloric Acid SCHEMBL3847812 | 0.83 | LOXL2 (0.94) | LOXL2MAOBTAAR1HRH3IDO1 | |
| Bromide SCHEMBL31513710 | 0.83 | LOXL2 (0.94) | LOXL2MAOBTAAR1HRH3IDO1 | |
| Ammonia Solution, Strong SCHEMBL4750128 | 0.83 | LOXL2 (0.94) | LOXL2MAOBTAAR1HRH3IDO1 | |
| SCHEMBL31456969 | 0.82 | LOXL2 (0.48) | LOXL2MAOBTAAR1KCNH3IDO1 | |
| Hydrochloric Acid SCHEMBL31473439 | 0.80 | MEN1 (0.50) | LOXL2MAOBKCNH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| EP-2401256-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | LOXL2 4199/4885MAOB 1822/4885TAAR1 851/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | LOXL2 4199/4885MAOB 1822/4885TAAR1 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.